The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

A new study shows that the US is still behind in controlling the price of prescription drugs. One doctor explains why America ...

Could ultra-processed foods be fueling your psoriasis? A new study suggests a link between high consumption of these foods ...

From tumor necrosis factor alpha (TNF-α), to IL-17 inhibitors, and then to IL-23 inhibitors, biologics have brought new light ...

Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition ...

Alumis is advancing ESK-001 for plaque psoriasis with phase 3 data expected in 2026. Read why ALMS stock is compelling yet ...

The increasing cases of skin diseases are forecast the fuel the growth of the scar treatment market. Vitiligo, psoriasis, eczema, and photoaging are skin diseases that demand proper treatment. Thus, ...

Risankizumab had greater improvements in skin clearance and quality of life at 16 weeks in patients with psoriasis compared with deucravacitinib.

Psoriasis severity and systemic inflammation linked to cardiovascular disease: insights for better patient care.

However, the finding held even after the French team factored out age, alcohol intake, body mass index (an estimate of fat ...